ArticleJournal of veterinary internal medicine2020
Amyloid-beta plasma and cerebrospinal fluid biomarkers in aged dogs with cognitive dysfunction syndrome.
Article in Journal of veterinary internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Advances in biomarker discovery for canine cognitive dysfunction: a comprehensive structured narrative review and future perspectives.Veterinary research communications · 2026Review
- Proteomic Analysis of Tear Film in Dogs and Cats: Emerging Biomarkers of Cognitive Dysfunction and Neurodegenerative Disorders.Animals : an open access journal from MDPI · 2026Review
- Nutrition Research in Aging Dogs and Cats: What We Know and What We Need to Do.Animals : an open access journal from MDPI · 2026Review
- Diffusion tensor imaging analysis of aged dogs with and without canine cognitive dysfunction.BMC veterinary research · 2025Article
- The companion dog as a translational model for Alzheimer's disease: Development of a longitudinal research platform and post mortem protocols.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Diagnosis of Canine Cognitive Dysfunction Syndrome: A Narrative Review.Veterinary sciences · 2025Review
- Evaluation of Blood-Based Diagnostic Biomarkers for Canine Cognitive Dysfunction Syndrome.Animals : an open access journal from MDPI · 2025Article
- Blood-brain barrier permeability changes in dogs with suspected canine cognitive dysfunction using magnetic resonance imaging subtraction enhancement analysis.Frontiers in veterinary science · 2025Article
- On the utility of cerebrospinal fluid biomarkers in canine neurological disorders.Scientific reports · 2024Article
- Protein profiling and assessment of amyloid beta levels in plasma in canine refractory epilepsy.Frontiers in veterinary science · 2023Article
- Potential revival of cholinesterase inhibitors as drugs in veterinary medicine.Frontiers in veterinary science · 2023Review
- Assessment of risk factors in dogs with presumptive advanced canine cognitive dysfunction.Frontiers in veterinary science · 2022Article
- Successful and Unsuccessful Brain Aging in Pets: Pathophysiological Mechanisms behind Clinical Signs and Potential Benefits from Palmitoylethanolamide Nutritional Intervention.Animals : an open access journal from MDPI · 2021Review
- Sustained Gaze Is a Reliable In-home Test of Attention for Aging Pet Dogs.Frontiers in veterinary science · 2021Article
- Amyloid-beta plasma and cerebrospinal fluid biomarkers in aged dogs with cognitive dysfunction syndrome.Journal of veterinary internal medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCognitive dysfunction syndrome (CDS) is a common progressive neurodegenerative disease that is poorly defined. Specific multitargeted protocols do not exist for setting the diagnosis and the prognosis of the syndrome. HYPOTHESIS/
objectivesTo quantify Aβ42 and Aβ40 peptides in blood and cerebrospinal fluid (CSF) and to investigate their contribution to CCDS. ANIMALS: A total of 61 dogs from a hospital population.
methodsCase-control study. Six young (YG: 0-4 years old), 8 middle-aged (4-8 years old), 17 cognitively unimpaired and aged (CU: 8-20 years old), and 30 cognitively impaired and aged (CI: 8-17 years). From the CI group, 10 dogs exhibited mild impairment (CI-MCI) and 20 exhibited severe impairment (CI-SCI). Cognitive status was assessed using a validated owner-based questionnaire. Direct and indirect Aβ markers were determined in plasma fractions (total-TP, free-FP, bound to plasma components-CP) and CSF using commercial ELISA assays (AΒtest, Araclon Biotech).
resultsTPAβ42/40 facilitated discrimination between CI-MCI and CU aged dogs with area under curve ≥ 0.79. CSFAβ42 levels were higher (P = .09) in CU (1.25 ± 0.28 ng/mL) than in MCI (1.04 ± 0.32 ng/mL) dogs. CSF Aβ42 levels were correlated with the CP fragment (CPAβ40: P = .02, CPAβ42: P = .02). CPAβ42 was higher in the CI-MCI (23.03 ± 11.79 pg/μL) group compared to the other aged dogs (CU: 10.42 ± 7.18 pg/μL, P = .02, SCI: 11.40 ± 12.98 pg/μL, P = .26). CONCLUSION AND CLINICAL IMPORTANCE: The Aβ should be determined in all of the 3 plasma fractions (TP, FP, CP). In the clinical approach, TPAβ42/40 could be used as an efficient preselection tool for the aged canine population targeting dogs with mild cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.